Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist not yet approved by the MHRA or EMA
doi: 10.1016/j.molmet.2023.101850 38 LeiCTWeiYHTangHWenQYeCZhangCet al
Factors that may influence protocol design include: The nature and location of the injury Activity level and physical demands Age and recovery history Concurrent treatments or medications Clinicians such as those affiliated with Pulse and Remedy emphasize that peptide protocols should evolve over time, with adjustments based on patient response and ongoing evaluation
If in doubt, seek advice from experienced investigators or clinicians used to working with peptides.
Everyone has been so helpful and has helped me feel much more excited about the process
The pathogenesis involves a breakdown of self-tolerance, enhanced antigen presentation, T and B lymphocyte activation, autoantibody production, and cytokine-mediated thyroid tissue damage